Jean-Patrick Demonsang

Président chez Demonsang Consulting SAS

71 ans

Finance

Health Technology

Consumer Services

Postes actifs de Jean-Patrick Demonsang

Sociétés	Poste	Début	Fin
Demonsang Consulting SAS	Président	-	-

Sociétés	Poste	Début	Fin
OSE IMMUNOTHERAPEUTICS	Directeur/Membre du Conseil	10/04/2014	22/06/2023
OSE IMMUNOTHERAPEUTICS	Independent Dir/Board Member	10/04/2014	22/06/2023
Seventure Partners SA Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.	Directeur Général	21/06/2010	01/01/2013
	Président	01/09/1999	01/01/2013
	President	01/09/1999	01/01/2013
Natixis Venture Sélection SA Natixis Venture Sélection SA Investment ManagersFinance Natixis Venture Selection SA seeks to invest in French companies operating in a wide range of sectors, it focuses on early and later venture capital stages.	Directeur/Membre du Conseil	-	-
Genode Partners SAS	Directeur Général	-	-
Parexi SAS	Président	-	-
G1j Ile De France	Président	-	-
Orphan Synergy Europe-Pharma SA Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France.	Directeur/Membre du Conseil	10/04/2014	-
	Independent Dir/Board Member	10/04/2014	-

École des Hautes Études Commerciales de Paris

Masters Business Admin

Internationale

France

Opérationnelle

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
OSE IMMUNOTHERAPEUTICS	Health Technology

Entreprise privées	7
Seventure Partners SA Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris.	Finance
Orphan Synergy Europe-Pharma SA Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France.	Health Technology
Demonsang Consulting SAS
G1j Ile De France
Parexi SAS
Genode Partners SAS
Natixis Venture Sélection SA Natixis Venture Sélection SA Investment ManagersFinance Natixis Venture Selection SA seeks to invest in French companies operating in a wide range of sectors, it focuses on early and later venture capital stages.	Finance